わかもと製薬(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証STD | 医薬品 | 4512/E00928 | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2020/01/31 | 日証協 | 455,036株 | +42.76% | 336,300株 | -34.03% | 481,433株 | +39.49% | 33,700株 | -79.45% |
2020/01/24 | 日証協 | 318,736株 | +2.21% | 509,800株 | +54.34% | 345,133株 | +1.05% | 164,000株 | +525.95% |
2020/01/17 | 日証協 | 311,836株 | +2.93% | 330,300株 | +11.13% | 341,533株 | +6.62% | 26,200株 | -37.62% |
2020/01/10 | 日証協 | 302,948株 | +14.91% | 297,212株 | +2964.04% | 320,333株 | +12.5% | 42,000株 | +9999.99% |
2019/12/30 | 日証協 | 263,648株 | -2.94% | 9,700株 | -94.3% | 284,733株 | +0.04% | 200株 | -98.59% |
2019/12/27 | 日証協 | 271,648株 | +3.39% | 170,200株 | +430.02% | 284,633株 | -35.74% | 14,200株 | -32.66% |
2019/12/20 | 日証協 | 262,748株 | -3.7% | 32,112株 | +277.79% | 442,924株 | +51.93% | 21,088株 | -87.92% |
2019/12/13 | 日証協 | 272,836株 | -3.5% | 8,500株 | -95.59% | 291,524株 | -16.81% | 174,600株 | +751.71% |
2019/12/06 | 日証協 | 282,736株 | -3.25% | 192,900株 | -3.07% | 350,424株 | +3.27% | 20,500株 | +310% |
2019/11/29 | 日証協 | 292,245株 | -2.15% | 199,000株 | +54.59% | 339,333株 | -4.98% | 5,000株 | -76.3% |
2019/11/22 | 日証協 | 298,657株 | -1.61% | 128,724株 | +14.22% | 357,133株 | -6.93% | 21,100株 | +51.8% |
2019/11/15 | 日証協 | 303,545株 | -1.17% | 112,700株 | +274.42% | 383,733株 | -6.35% | 13,900株 | +826.67% |
2019/11/08 | 日証協 | 307,145株 | +0.62% | 30,100株 | -77.05% | 409,733株 | +0.34% | 1,500株 | -83.87% |
2019/11/01 | 日証協 | 305,245株 | +7.7% | 131,136株 | +836.69% | 408,333株 | -2.67% | 9,300株 | +389.47% |
2019/10/25 | 日証協 | 283,409株 | -1.49% | 14,000株 | -86.1% | 419,533株 | +0.1% | 1,900株 | -63.46% |
2019/10/18 | 日証協 | 287,709株 | -1.91% | 100,700株 | -7.95% | 419,133株 | -1.11% | 5,200株 | -66.88% |
2019/10/11 | 日証協 | 293,309株 | -0.81% | 109,400株 | -62.8% | 423,833株 | +1.63% | 15,700株 | -32.07% |
2019/10/04 | 日証協 | 295,709株 | -1.76% | 294,100株 | +154.41% | 417,033株 | +0.05% | 23,111株 | +579.54% |
2019/09/27 | 日証協 | 301,000株 | -1.05% | 115,600株 | -9.78% | 416,813株 | -4.49% | 3,401株 | -75.53% |
※株式分割は考慮していませんのでご注意ください。
Page Top